Molecure S.A. (WSE:MOC)

Poland flag Poland · Delayed Price · Currency is PLN
7.90
+0.03 (0.38%)
Aug 14, 2025, 5:00 PM CET
0.38%
Market Cap159.61M
Revenue (ttm)3.49M
Net Income (ttm)-29.63M
Shares Out20.20M
EPS (ttm)-1.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,838
Average Volume90,695
Open7.88
Previous Close7.87
Day's Range7.78 - 7.95
52-Week Range5.15 - 16.70
Beta2.44
RSI58.70
Earnings DateSep 30, 2025

About Molecure

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 102
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MOC
Full Company Profile

Financial Performance

In 2024, Molecure's revenue was 2.92 million, a decrease of -20.08% compared to the previous year's 3.65 million. Losses were -31.29 million, 10.3% more than in 2023.

Financial Statements

News

There is no news available yet.